- 1 Association between Cardiovascular Disease Risk and long COVID-19: A
- 2 Systematic Review and Meta-analysis
- 3 Yunxia Huang<sup>a, b</sup>, Zhuofeng Wen<sup>a, b</sup>, Hongbin Luo<sup>a, b</sup>, Yijie Liao<sup>a, b</sup>, Zisheng Chen<sup>a, \*</sup>
- <sup>a</sup>Department of Respiratory and Critical Care Medicine, the Sixth Affiliated Hospital
- of Guangzhou Medical University, Qingyuan People's Hospital, Qingyuan 511518,
- 6 China;

13

19

- <sup>b</sup>The Sixth Clinical Medical School of Guangzhou Medical University;
- 8 \* Corresponding author: E-mail addresses: williamstdb@gzhmu.edu.cn.
- 10 ABSTRACT
- 11 **Objectivate** To assess demographic characteristics and investigate the correlation
- between cardiovascular diseases and long COVID-19 patients.
- Methods Comprehensive details, encompassing the first author's name, publication
- 15 year, sample inclusion criteria, sample size, and demographic characteristics,
- including age and gender of participants, were systematically extracted from all
- incorporated studies. Meanwhile, the analysis encompassed the assessment of the risk
- associated with nineteen cardiovascular outcomes.
- 21 **Results** A total of 3, 201 potentially eligible studies were initially identified for
- consideration. Following rigorous literature screening and quality control measures,
  NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

43

eighteen studies, encompassing 46, 083, 975 patients, met the specified criteria. In comparison to the control cohort, our investigation unveiled a heightened risk of 19 cardiovascular outcomes associated with long COVID-19. Our meta-analysis revealed a pooled OR of 1.68 (95% CI 1.55-1.81) ( $I^2 = 69.1\%$ , p= 0.000) for the overall risk of cardiovascular outcomes, indicating an elevated risk of cardiovascular diseases in individuals affected by long COVID-19. While the heterogeneity was relatively high, it is essential to acknowledge that all studies inherently carry an unavoidable risk of bias, irrespective of their quality rating. Moreover, there appears to be no significant publication bias based on the funnel plot, Begg's, and Egger's tests. Sensitivity analysis did not reveal substantial alterations in the overall stability of the results. Conclusions Our meta-analysis substantiates that individuals afflicted with long COVID-19 face an elevated risk of developing cardiovascular diseases. Routine assessment of cardiac function is deemed essential for a long COVID-19 high-risk cardiovascular disease population. Timely interventions have the potential to mitigate

### TRIAL REGISTRATION PROSPERO Identifier: CRD42023455701

the risk of cardiovascular diseases and associated mortality in this population.

- **Keywords:** Coronavirus disease 2019; Cardiovascular Disease; Long COVID-19. 42
- Abbreviations: WHO, World Health Organization; HR, Hazard ratio; RR, risk ratio; 44

OR, odds ratio; CI, confidence interval; REM, random-effects model; ACE2,

angiotensin-converting enzyme 2; SARS-CoV-2, Severe Acute Respiratory

Syndrome Coronavirus 2 CoV; MESH, Medical Subject Headings; NOS,

Newcastle-Ottawa Scale; FEM, fixed-effect model; BMI, Body Mass Index; IL,

interleukin;

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

### 1. Introduction

Since the COVID-19 global pandemic, there have been over 771, 151, 224 cumulative cases and 6, 960, 783 deaths of COVID-19 all over the world, as of 4 October 2023<sup>1</sup>. Recently, more and more researches have posited that COVID-19 may exert deleterious effects on patients beyond the acute phase, including potential negative impacts on respiratory, neurologic, mental, gastrointestinal, and cardiovascular health<sup>2-5</sup>. Consequently, the terminology 'long COVID' or 'post-COVID-19 syndrome' has emerged, specifically denoting the persistent clinical manifestations observed beyond the acute phase<sup>6</sup>. This fluctuating condition can be classified into two stages, namely post-acute and chronic, delineated by the duration of follow-up during which the symptoms manifest<sup>7</sup>. In the view of some studies, approximately one-eighth of the global population is projected to experience post-COVID-19 conditions. This implies that, considering over 651 million documented COVID-19 cases worldwide and a conservative estimate of a 10% incidence rate among infected individuals, around 65 million individuals worldwide may be affected by long COVID<sup>8,9</sup>. During the trajectory of long COVID-19, prevalent symptoms and signs include olfactory

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

dysfunction, dyspnea, gustatory dysfunction, cough, fatigue, myalgia, among others, contributing to a diminished quality of life and decreased work efficiency 10. Moreover, COVID-19 is implicated in significant multiorgan dysfunction, encompassing myocardial injury, acute respiratory distress syndrome, systemic shock, liver injury, renal injury, etc<sup>11,12</sup>. Relevant studies suggest that the zinc metallopeptidase angiotensin-converting enzyme 2 (ACE2), responsible for converting angiotensin II to angiotensin, serves as the functional receptor for Severe Acute Respiratory Syndrome Coronavirus 2 CoV (SARS-CoV-2), whose interaction is implicated in myocardial damage, representing one potential mechanism, but the specific mechanisms remain elusive <sup>13,14</sup>. As matters stand, there is an increasing number of reports highlighting cardiovascular complications in long COVID, including arrhythmia, inflammatory heart disease, heart failure and various other cardiac disorders 15,16. Actually, we have to acknowledge the existing controversy still surrounding the relationship between cardiovascular disease and long COVID-19. Specifically, regarding ischemic heart disease, findings from Hannah R Whittaker et al<sup>2</sup> suggest a lower risk for long COVID-19 patients, while studies by Kwan Hong et al<sup>17</sup> and Yan Xie et al<sup>18</sup> present contrasting perspectives. Consequently, our current understanding of the association between cardiovascular disease and long COVID-19 remains limited. Further comprehensive evidence is imperative to establish a definitive association between

cardiovascular disease and patients with long COVID-19.

As a consequence, we analyzed and reviewed relevant cohort studies to sort out the association of long COVID-19 patients with cardiovascular disease risk by the mean of meta-analysis comprehensively and deeply.

#### 2. Materials and methods

### 2. 1. Literature search

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

We performed a comprehensive meta-analysis of prospective and retrospective cohort studies documenting at least one combination of risk factors and outcomes. Our search strategy encompassed multiple databases, such as Web of Science, Scopus, Cochrane Library, Embase and PubMed, up to August 18, 2023, and was limited to articles published solely in English. Our search used the keywords "long COVID-19", "cardiovascular disease" and their Medical Subject Headings (MeSH) terms. Studies were required to fulfill the following medical standards: (1) only include prospective/retrospective cohort studies and case-control studies; (2) Patients with long COVID-19 were studied; (3) Outcome indicators: the risk of cardiovascular disease among patients with confirmed long COVID-19 (HR, RR and OR, with 95% CI); (4) Written in English only. Studies were excluded if they lacked the provision of OR/RR/HR with 95% CI, exhibited poor methodological quality, reported individual cases, or lacked the specified indicators of accomplishment mentioned above. Our research was registered in the Prospective Register of Systematic Reviews (PROSPERO ID CRD42023455701).

2. 2. Data acquisition

Four investigators (Y. H., Z. W., H. L., Y. L.) independently extracted data and resolved discrepancies through consensus by four reviewers. The results underwent review by the senior investigator (Z. C.). When available, information on target outcomes was documented using WPS software. General details, including the first author's name, publication year, sample inclusion criteria, sample size, and demographic data such as age and gender of study participants, were systematically collected from all included studies. Incidence outcomes were compared between the COVID-19 and non-COVID-19 groups.

### 2. 3. Quality assessment

The risk of bias in the included cohort studies was evaluated using the Newcastle-Ottawa Scale (NOS). Studies achieving a score of at least 7 out of 10 were classified as high-quality studies.

### 2. 4. Statistical analyses in Meta-analysis

We conducted meta-analyses using a statistical software package (Stata 11.0). Heterogeneity among the studies was assessed through  $\chi 2$  analysis. If the inconsistency values ( $I^2$ ) exceeded 50%, a REM was applied; otherwise, a fixed-effect model (FEM) was utilized. In the presence of heterogeneity, we explored its source through subgroup analysis and sensitivity analysis. The combined HR, RR, OR, with

its corresponding 95% CI was computed. Subsequently, funnel plots, Begg and Egger bias index tests, and meta-regression were employed to identify potential publication bias. All P values were two-sided, and statistical significance was set at P < 0.05.

### 3. Results

### 3. 1. Search results and study characteristics

The selection process is depicted in Figure. 1 via a flowchart. 3, 201 studies were deemed potentially eligible across various databases. 591 duplicates were excluded, then 2610 left. After extensively comparing the studies' relevant information, 1, 001 researchers were included, but 1,609 were excluded (150 case reports, 371 conference abstracts, 197 comments, 20 editorials, 71 letters, 117 notes, 631 review, 52 meta-analyses). According to the studies for the title and abstract screening, 136 articles were taken into the next round, and 865 were dismissed (60 not related to COVID-19, 270 irrelevant research, 513 about other diseases, 22 not cohort studies). Finally, eighteen articles remained after reading the full articles, and 118 were ruled out (17 studies with incomplete outcomes, 88 irrelevant researches, 13 irrelevant interventions).

The characteristics of the included studies are presented in Table. 1 Eighteen cohort studies, including 3 prospective cohort studies and 15 retrospective cohort studies, were conducted in developed and developing countries involving different races. The total number of patients included in these studies was 46, 083, 975 of which more

than 37, 475, 604 were in the no COVID-19 group, and over 8, 327, 779 were in the COVID-19 group. The duration of the studies ranged from 5 to 39 months. The male ranged from 41.2% to 90.42%, and the mean age of the participants ranged from 27.99 ( $\pm 7.96$ ) to 73.85 ( $\pm 4.50$ ) years. Only seven studies reported the mean Body Mass Index (BMI) of the no COVID-19 group, which ranged from 26 ( $\pm 5.0$ ) kg/m<sup>2</sup> to 30.2 (±5.7) kg/m<sup>2</sup>, while the mean BMI of the COVID-19 group ranged from 27.1  $(\pm 6.7)$  kg/m<sup>2</sup> to 31.00  $(\pm 6.06)$  kg/m<sup>2</sup>. Furthermore, there were eight studies collected the smoking history of the individuals: 5.52% to 57.43% in no COVID-19 group while 4.41% to 59.69% in COVID-19 group. In addition, eleven researches provided the prevalence of diabetes: 7.42% to 77.22% in no COVID-19 group while 8.34% to 75.61% in COVID-19 group. What's more, there were also five studies recorded the prevalence of high cholesterol: 8.63% to 74.29% in no COVID-19 group while 8.80% to 72.79% in COVID-19 group. Lastly, three articles mentioned the morbidity of coronary heart disease: 22.12% to 78.21% in no COVID-19 group, then, 22.12% to 35.74% in COVID-19 group.

### 3. 2. Quality assessment

We used the NOS, a measure of bias, to analyze the case-control and cohort studies.

Only studies at least with a minimum score of 7 were deemed to be of high quality. In

our meta-analysis, fifteen articles had a performance score of more than 7<sup>2-4,16-27</sup>, and

three studies scored 6 as medium quality <sup>28-30</sup>, as shown in Table. 2.

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

173

174

# 3. 3. 1 Cardiovascular disease risk in long COVID-19 patients

- Compared to the control cohort, our meta-analysis showed a pooled OR of 1.87 (95%) 178 CI 1.56-2.25) ( $I^2 = 99.4\%$ , p= 0.000) for the overall risk of cardiovascular events, 179 while major cardiovascular diseases (HR 1.52; 95% CI, 1.42-1.63;  $I^2 = 69.1\%$ , P= 180 0.021) and cardiovascular mortality (HR 1.65; 95% CI, 1.12-2.43;  $I^2 = 39.7\%$ , P= 181 0.173), indicating a higher risk among long COVID-19 patients (Supplementary 182 material online, Appendix Figure. 1 A-C) 183 184 We noted a significant positive association between long COVID-19 and 17 185 cardiovascular disease outcomes, consisting of acute coronary disease (RR 1.44; 95% 186 CI, 1.21-1.70;  $I^2 = 87.8\%$ , P = 0.000) (Supplementary material online, Appendix 187 Figure. 2), angina (RR 1.33; 95% CI, 1.17-1.52;  $I^2 = 80.4\%$ , P = 0.000) 188 (Supplementary material online, Appendix Figure. 3A), arrhythmia (RR 1.99; 95% 189 CI, 1.44-2.74;  $I^2 = 98.3\%$ , P = 0.000) (Supplementary material online, Appendix 190 Figure. 4A), atrial fibrillation (OR 1.48; 95% CI, 1.25-1.75;  $I^2 = 93.3\%$ , P = 0.000) 191 (Supplementary material online, Appendix Figure. 5A), atrial flutter (RR 1.31; 95% 192 CI, 0.97-1.76;  $I^2 = 92.2\%$ , P = 0.000) (Supplementary material online, Appendix 193 Figure. 6), bradycardia (OR 1.48; 95% CI, 1.34-1.64;  $I^2 = 88.2\%$ , P = 0.000) 194 (Supplementary material online, Appendix Figure. 7), cardiac arrest (RR 1.95; 95% 195 CI, 1.48-2.58;  $I^2 = 63.4\%$ , P = 0.018) (Supplementary material online, Appendix 196
- Figure. 8), cardiogenic shock (RR 1.85; 95% CI, 1.59-2.14;  $I^2 = 0.0\%$ , P = 0.604) 197
- (Supplementary material online, Appendix Figure. 9), cardiomyopathy (RR 1.52; 95% 198

CI, 1.25-1.83;  $I^2 = 93.4\%$ , P = 0.000) (Supplementary material online, Appendix 199 Figure. 10A), coronary disease(HR 1.65; 95% CI, 1.28-2.14;  $I^2 = 81.7\%$ , P = 0.004) 200 (Supplementary material online, Appendix Figure. 11), heart failure (OR 1.77; 95% 201 CI, 1.52-2.05;  $I^2 = 96.4\%$ , P = 0.000) (Supplementary material online, Appendix 202 Figure. 12A), hypertension (HR 2.39; 95% CI, 0.60-9.62;  $I^2 = 99.6\%$ , P = 0.000) 203 (Supplementary material online, Appendix Figure. 13), ischemic heart disease (HR 204 1.49; 95% CI, 1.13-1.96;  $I^2 = 97.3\%$ , P = 0.000) (Supplementary material online, 205 Appendix Figure. 14), myocardial infarction (OR 1.63; 95% CI, 1.42-1.86;  $I^2 = 80.9\%$ , 206 P= 0.000) (Supplementary material online, Appendix Figure. 15), myocarditis (OR 207 4.42; 95% CI. 2.94-6.67;  $I^2 = 69.7\%$ , P = 0.000) (Supplementary material online. 208 Appendix Figure. 16), pericarditis (OR 2.07; 95% CI, 1.59-2.69;  $I^2 = 85.9\%$ , P = 0.000) 209 (Supplementary material online, Appendix Figure. 17) and tachycardia (OR 1.76; 95% 210 CI, 1.63-1.90;  $I^2 = 82.8\%$ , P = 0.000) (Supplementary material online, Appendix 211 Figure. 18). 212 213 Long COVID-19 patients had a higher risk of developing cardiovascular disease risk 214 in relevant studies generally, according to the combined multivariate RR of 19 215 outcomes. A forest plot of the OR is shown in Figure. 2. We noted a significant 216 positive association between long COVID-19 and 19 cardiovascular disease outcomes 217 (RR 1.68; 95% CI, 1.55-1.81;  $I^2 = 69.1\%$ , P = 0.000). 218 219

The combined univariable OR of 4 outcomes was as well carried out, heart failure

(OR 1.56; 95% CI, 0.66-3.73;  $I^2 = 97.6\%$ , P = 0.000), myocarditis (OR 2.72; 95% CI, 221

0.40-18.32;  $I^2 = 95.1\%$ , P = 0.000), myocardial infarction (OR 2.37; 95% CI, 222

0.74-7.61;  $I^2 = 77.5\%$ , P = 0.035), pericarditis (OR 1.47; 95% CI, 0.29-7.42;  $I^2 = 94$ . 223

9%, P= 0.000), suggesting that confounding factors are prevalent, potentially 224

compromising the reliability of the results in univariate analysis, as shown in Figure.

3. However, the significance of aggregated analysis persists (OR 1.97; 95% CI, 226

1.11-3.52;  $I^2 = 95.5\%$ , P = 0.000). 227

225

228

229

242

# 3. 3. 2 Subgroup Analysis

A subgroup analysis was performed according to type of inpatient and outpatient, for 230 inpatient: angina (RR 1.70; 95% CI, 0.97-2.99;  $I^2 = 87.9\%$ , P = 0.004) and heart 231 failure (RR 1.47; 95% CI, 1.21-1.79;  $I^2 = 86.0\%$ , P = 0.000), as shown in 232 Supplementary material online, Appendix Figure. 3B and 12B, respectively; for 233 outpatient atrial fibrillation and flutter (RR 1.11; 95% CI, 0.82-1.52;  $I^2 = 87.4\%$ , P= 234 0.005) and heart failure ( RR 1.06; 95% CI, 0.95-1.17;  $I^2 = 0.0\%$ , P = 0.879), as shown 235 in Supplementary material online, Appendix Figure. 5B and 12B, respectively. 236 Judging from the outcomes, it showed that the risk of HF significantly increased in 237 the inpatient group, may reflect severe COVID-19 would increase the risk of 238 long-term HF to some extent. Furthermore, there were 2 main subgroups for the 239 pathological type of cardiomyopathy, the subgroup analysis of ischemic 240 cardiomyopathy (RR 1.58; 95% CI, 1.11-2.26; I<sup>2</sup> = 92.7%, P= 0.000) and 241 non-ischemic cardiomyopathy (RR 1.34; 95% CI, 1.10-1.64;  $I^2 = 78.8\%$ , P = 0.000),

as shown in Supplementary material online, Appendix Figure. 10B.

Supplementary material online, Appendix Figure. 4B and 5C.

Meanwhile, there were also two other subgroup analyses, comprising ventricular arrhythmias (RR 1.70; 95% CI, 1.36-2.13;  $I^2$  = 84.9%, P= 0.000) and atrial fibrillation and flutter (RR 1.78; 95% CI, 0.97-3.25;  $I^2$  =98.5%, P= 0.000), as shown in

Considering the limitation of retrospective cohort study, we also conducted the risk of cardiovascular outcomes only based on prospective cohort studies, which is more reliable. It displayed that atrial fibrillation (HR 1.60; 95% CI, 0.87-2.95;  $I^2 = 94.6\%$ , P= 0.000), heart failure (HR 1.74; 95% CI, 1.25-2.41;  $I^2 = 65.9\%$ , P= 0.053), pericarditis (HR 4.47; 95% CI, 3.15-6.35;  $I^2 = 0.0\%$ , P= 0.996), as shown in Supplementary material online, Appendix Figure. 19. Also Pooled analysis demonstrates the significance of the aforementioned three outcomes (HR 2.14; 95% CI, 1.52-3.01;  $I^2 = 89.6\%$ , P= 0.000).

# 3. 4. Heterogeneity and publication bias

The heterogeneity was relatively high, but with the help of Meta-regression, we figured out that country, study design, total number of samples, age at baseline and total months of follow-up should be responsible for sources of heterogeneity to a certain extent Supplementary material online, Appendix Figure. 20-39). Meanwhile, owing to the observational research's character, all studies

inherently entail an inevitable risk of bias, irrespective of their quality rating<sup>31</sup>. The results of the funnel plot, Begg's, and Egger's tests collectively indicated the absence of publication bias in the meta-analysis basically (Supplementary material online, Appendix Figure. 40, Supplementary material online, Appendix Table. 2-19).

## 3. 5. Sensitivity analysis

Regarding the results displayed above, there was no discernible alteration in the stability of the meta-analysis (Supplementary material online, Appendix Figure. 41).

### 4. Discussion

At present, a definitive mechanism explaining the pathophysiology of long-COVID contributing to cardiovascular diseases remains not conclusive. One hypothesis proposes that myocardial injury in COVID-19 may arise from either direct viral invasion of cardiomyocytes or the presence of circulating inflammatory mediators, including cytokines and/or endotoxins, or potentially a combination of both factors<sup>32</sup>. Upon infection, there was an observed upregulation of ACE2, the receptor for SARS-CoV-2, in the pulmonary alveolar epithelial barrier, vascular endothelial cells, and cardiomyocytes<sup>33</sup>. In single-nuclei RNA sequencing studies, robust expression of ACE2 in the heart is evident in pericytes, vascular smooth muscle cells, fibroblasts, and cardiomyocytes<sup>34</sup>. An alternative hypothesis suggests that both hypo- and hyper-immune responses may play a role in the severity of COVID-19, potentially leading to systemic inflammatory responses or a cytokine storm, culminating in cell

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

death and multi-organ dysfunction<sup>35</sup>. According to cell and animal models of SARS-CoV-2 infection, coupled with transcriptional and serum profiling of individuals with COVID-19, one experiment revealed a consistent and distinctive inflammatory reaction, whose response was characterized by reduced levels of type I and III interferons concomitant with elevated chemokine levels and prominent expression of Interleukin- 6 (IL-6)<sup>36</sup>.

Numerous cohort studies have identified an association between long-term COVID-19 and diverse cardiovascular outcomes. However, a comprehensive systematic meta-analysis assessing composite cardiac outcomes is currently lacking. This study employed meta-analysis techniques to evaluate the relationship between long COVID-19 and cardiovascular outcomes. Our meta-analysis, based on the scrutiny of 18 articles comprising both retrospective and prospective studies, encompassing 46, 083, 975 participants, revealed that individuals with long COVID-19 face an increased risk of developing cardiovascular diseases overall. Although the relatively high heterogeneity is acknowledged, it is inevitable for the diversity arising from variations in countries, study designs, total sample sizes, baseline ages, and durations of follow-up, as revealed by the results of meta-regression. Additionally, the complexity of confounding factors presents a challenge in achieving complete standardization. All included studies, even those with a high rating, inherently entail an unavoidable risk of bias, owing to their observational characteristic<sup>31</sup>. And we also hope to collect the data of long Covid patients' BMI<sup>37</sup>, smoking status<sup>38-40</sup>, diabetes<sup>41</sup>, high cholesterol<sup>42,43</sup>, vaccination<sup>44-46</sup> etc as much as possible, further identifying sources of heterogeneity. But in our study, all the HRs, RRs and ORs are all over >1.0, as well as the absence of publication bias based on the results of the funnel plot, Begg's, and Egger's tests, suggesting the model is robust and reliable.

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

Hence, we propose that routine assessment of cardiac function is imperative for the population with long COVID-19 who are at a heightened risk of cardiovascular disease. Timely interventions have the potential to mitigate the risk of cardiovascular diseases and associated mortality. At present, the management of long COVID and CV sequelae encompass a range of therapeutic interventions<sup>5</sup>: these interventions comprise various rehabilitation programs, both through telemedicine and in-person consultations, targeting the amelioration of symptoms such as fatigue, cognitive decline, and breathlessness; additionally, immunomodulatory treatments, including steroids, laranilubmab, tocilizumab, atorvastatin, and colchicine, are also under scrutiny; meanwhile, antifibrotic agents, like pirfenidone and LYT-100, as well as anticoagulation strategies employing apixaban, are being experimented; furthermore, there are therapies directed towards cognition enhancement, such as transcranial stimulation, as well as metabolic modulators like niagen. What's more, Paxlovid demonstrates higher efficacy in those harboring preexisting neurological or cardiovascular conditions, individuals with immunosuppression and older patients<sup>47</sup>. But, the preeminent strategy for averting severe complications stemming from SARS-CoV-2 infection is still vaccination<sup>48,49</sup>. Furthermore, vigilant monitoring of viral infection-associated cardiac injury remains imperative throughout the management of COVID-19.

### 5. Limitations

We acknowledge certain limitations in our study that warrant consideration. Firstly, several of our conducted meta-analyses displayed notable statistical heterogeneity, which may potentially lead to an overestimation of the strength of associations, as suggested by large meta-epidemiologic studies. The observed heterogeneity may be attributed to adjusted confounding factors and other variables within the included studies. Additionally, among the 18 articles analyzed, special attention should be given to the cumulative duration of follow-up, given the chronic nature of SARS-CoV-2 infection. Furthermore, retrospective cohort studies inherently introduce a risk of bias. Therefore, there is an ongoing need for additional relevant cohort studies, particularly prospective cohort studies, to enable a more comprehensive analysis. But it is crucial to emphasize that all studies included in our analysis provided risk factors through multivariable regression, ensuring the derivation of robust conclusions.

### **6. Conclusions**

In summary, our study furnishes evidence indicating that individuals long COVID-19 face a markedly elevated risk of developing cardiovascular outcomes. Implementing

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

intensified vaccination strategies, particularly with the latest COVID-19 vaccine, in populations at a severe risk, and regularly monitoring cardiac function in those at a high cardiovascular risk, may prove beneficial in mitigating the risk of cardiovascular diseases and associated mortality in individuals with long COVID-19. **Author Contributions** Study design: ZC, YH; Data collection: YH, ZW, HL, YL; Data analyses: YH, ZC; Results visualization: YH; Results interpretations: YH, ZC; Manuscript writing: YH, ZC; Manuscript revising: YH, ZW, HL, YL ZC. All authors approved the final version of the manuscript. **Funding** Special fund project for clinical research of Qingyuan People's Hospital (QYRYCRC2023006), plan on enhancing scientific research in GMU (GZMU-SH-301). **Data Availability:** The research contributions presented in this article are detailed in the article/supplementary material; you can contact the relevant author for further information. **Declarations** 

Competing interests The authors declare that they have no competing interests.

#### Reference

376

- 378 1. World Health Organization. Weekly operational update on COVID-19—4 July 2021. Weekly operational update on COVID-19 4 October 2023 (who.int)
- 380 2. Whittaker HR, Gulea C, Koteci A, Kallis C, Morgan AD, Iwundu C, Weeks M, Gupta R, Quint JK.
- 381 GP consultation rates for sequelae after acute covid-19 in patients managed in the
- community or hospital in the UK: population based study. *BMJ*. 2021;375:e065834. doi:
- 383 10.1136/bmj-2021-065834
- 384 3. Wan EYF, Mathur S, Zhang R, Yan VKC, Lai FTT, Chui CSL, Li X, Wong CKH, Chan EWY, Yiu KH, et
- al. Association of COVID-19 with short- and long-term risk of cardiovascular disease and
- mortality: a prospective cohort in UK Biobank. *Cardiovasc Res.* 2023;119:1718-1727. doi:
- 387 10.1093/cvr/cvac195
- 388 4. Bowe B, Xie Y, Al-Aly Z. Postacute sequelae of COVID-19 at 2 years. *Nat Med*.
- 389 2023;29:2347-2357. doi: 10.1038/s41591-023-02521-2
- 390 5. Raman B, Bluemke DA, Luscher TF, Neubauer S. Long COVID: post-acute sequelae of
- 391 COVID-19 with a cardiovascular focus. Eur Heart J. 2022;43:1157-1172. doi:
- 392 10.1093/eurheartj/ehac031
- 393 6. Venkatesan P. NICE guideline on long COVID. *Lancet Respir Med.* 2021;9:129. doi:
- 394 10.1016/S2213-2600(21)00031-X
- 395 7. Fernandez-de-Las-Penas C. Long COVID: current definition. *Infection*. 2022;50:285-286. doi:
- 396 10.1007/s15010-021-01696-5
- 397 8. Ballering AV, van Zon SKR, Olde Hartman TC, Rosmalen JGM, Lifelines Corona Research I.
- 398 Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort
- 399 study. Lancet. 2022;400:452-461. doi: 10.1016/S0140-6736(22)01214-4
- 400 9. Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and
- 401 recommendations. *Nat Rev Microbiol*. 2023;21:133-146. doi: 10.1038/s41579-022-00846-2
- 402 10. Healey Q, Sheikh A, Daines L, Vasileiou E. Symptoms and signs of long COVID: A rapid review
- 403 and meta-analysis. J Glob Health. 2022;12:05014. doi: 10.7189/jogh.12.05014
- 404 11. Wang Y, Liu S, Liu H, Li W, Lin F, Jiang L, Li X, Xu P, Zhang L, Zhao L, et al. SARS-CoV-2 infection
- 405 of the liver directly contributes to hepatic impairment in patients with COVID-19. *J Hepatol*.
- 406 2020;73:807-816. doi: 10.1016/j.jhep.2020.05.002
- 407 12. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, et al. Clinical features of
- 408 patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;395:497-506.
- 409 doi: 10.1016/S0140-6736(20)30183-5
- 410 13. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. *Nat Rev Cardiol*.
- 411 2020;17:259-260. doi: 10.1038/s41569-020-0360-5
- 412 14. Turner AJ, Hiscox JA, Hooper NM. ACE2: from vasopeptidase to SARS virus receptor. Trends
- 413 *Pharmacol Sci.* 2004;25:291-294. doi: 10.1016/j.tips.2004.04.001
- 414 15. Sidik SM. Heart-disease risk soars after COVID even with a mild case. *Nature*. 2022;602:560.
- 415 doi: 10.1038/d41586-022-00403-0

- 416 16. Wang W, Wang CY, Wang SI, Wei JC. Long-term cardiovascular outcomes in COVID-19
- survivors among non-vaccinated population: A retrospective cohort study from the TriNetX
- 418 US collaborative networks. *EClinicalMedicine*. 2022;53:101619. doi:
- 419 10.1016/j.eclinm.2022.101619
- 420 17. Hong K, Kisiju T, Kim J, Chun BC. Cardio-cerebrovascular complications in COVID-19 patients:
- 421 A retrospective cohort study. Front Med (Lausanne). 2022;9:1045274. doi:
- 422 10.3389/fmed.2022.1045274
- 423 18. Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat Med.
- 424 2022;28:583-590. doi: 10.1038/s41591-022-01689-3
- 425 19. Bowe B, Xie Y, Al-Aly Z. Acute and postacute sequelae associated with SARS-CoV-2 reinfection.
- 426 *Nat Med*. 2022;28:2398-2405. doi: 10.1038/s41591-022-02051-3
- 427 20. Lip GYH, Genaidy A, Tran G, Marroquin P, Estes C. Incident atrial fibrillation and its risk
- 428 prediction in patients developing COVID-19: A machine learning based algorithm approach.
- 429 Eur J Intern Med. 2021;91:53-58. doi: 10.1016/j.ejim.2021.04.023
- 430 21. Salah HM, Fudim M, O'Neil ST, Manna A, Chute CG, Caughey MC. Post-recovery COVID-19 and
- 431 incident heart failure in the National COVID Cohort Collaborative (N3C) study. *Nat Commun*.
- 432 2022;13:4117. doi: 10.1038/s41467-022-31834-y
- 433 22. Lam ICH, Wong CKH, Zhang R, Chui CSL, Lai FTT, Li X, Chan EWY, Luo H, Zhang Q, Man KKC, et
- al. Long-term post-acute sequelae of COVID-19 infection: a retrospective, multi-database
- cohort study in Hong Kong and the UK. EClinicalMedicine. 2023;60:102000. doi:
- 436 10.1016/j.eclinm.2023.102000
- 437 23. Ortega-Paz L, Arevalos V, Fernandez-Rodriguez D, Jimenez-Diaz V, Baneras J, Campo G,
- 438 Rodriguez-Santamarta M, Diaz JF, Scardino C, Gomez-Alvarez Z, et al. One-year cardiovascular
- outcomes after coronavirus disease 2019: The cardiovascular COVID-19 registry. *PLoS One*.
- 440 2022;17:e0279333. doi: 10.1371/journal.pone.0279333
- 441 24. Tuvali O, Tshori S, Derazne E, Hannuna RR, Afek A, Haberman D, Sella G, George J. The
- Incidence of Myocarditis and Pericarditis in Post COVID-19 Unvaccinated Patients-A Large
- 443 Population-Based Study. J Clin Med. 2022;11. doi: 10.3390/jcm11082219
- 444 25. Mabila S, Patel D, Fan M, Stahlman S, Seliga N, Nowak G, Wells N. Post -acute sequalae of
- 445 COVID-19 and cardiac outcomes in U. S. military members. Int J Cardiol Cardiovasc Risk Prev.
- 446 2023;17:200183. doi: 10.1016/j.ijcrp.2023.200183
- 447 26. Raisi-Estabragh Z, Cooper J, Salih A, Raman B, Lee AM, Neubauer S, Harvey NC, Petersen SE.
- 448 Cardiovascular disease and mortality sequelae of COVID-19 in the UK Biobank. Heart.
- 449 2022;109:119-126. doi: 10.1136/heartjnl-2022-321492
- 450 27. Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19.
- 451 *Nature*. 2021;594:259-264. doi: 10.1038/s41586-021-03553-9
- 452 28. Katsoularis I, Fonseca-Rodriguez O, Farrington P, Lindmark K, Fors Connolly AM. Risk of acute
- 453 myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-controlled
- 454 case series and matched cohort study. *Lancet*. 2021;398:599-607. doi:
- 455 10.1016/S0140-6736(21)00896-5
- 456 29. Cohen K, Ren S, Heath K, Dasmarinas MC, Jubilo KG, Guo Y, Lipsitch M, Daugherty SE. Risk of
- 457 persistent and new clinical sequelae among adults aged 65 years and older during the
- 458 post-acute phase of SARS-CoV-2 infection: retrospective cohort study. *BMJ*.
- 459 2022;376:e068414. doi: 10.1136/bmj-2021-068414

- Zhang HG, Dagliati A, Shakeri Hossein Abad Z, Xiong X, Bonzel CL, Xia Z, Tan BWQ, Avillach P,
   Brat GA, Hong C, et al. International electronic health record-derived post-acute sequelae
- profiles of COVID-19 patients. *NPJ Digit Med*. 2022;5:81. doi: 10.1038/s41746-022-00623-8
- Tsampasian V, Elghazaly H, Chattopadhyay R, Debski M, Naing TKP, Garg P, Clark A, Ntatsaki E, Vassiliou VS. Risk Factors Associated With Post-COVID-19 Condition: A Systematic Review and
- 465 Meta-analysis. *JAMA Intern Med*. 2023;183:566-580. doi: 10.1001/jamainternmed.2023.0750
- Shi S, Qin M, Cai Y, Liu T, Shen B, Yang F, Cao S, Liu X, Xiang Y, Zhao Q, et al. Characteristics and
- clinical significance of myocardial injury in patients with severe coronavirus disease 2019. *Eur*
- 468 *Heart J.* 2020;41:2070-2079. doi: 10.1093/eurheartj/ehaa408
- 469 33. Ma S, Sun S, Li J, Fan Y, Qu J, Sun L, Wang S, Zhang Y, Yang S, Liu Z, et al. Single-cell
- 470 transcriptomic atlas of primate cardiopulmonary aging. *Cell Res.* 2021;31:415-432. doi:
- 471 10.1038/s41422-020-00412-6
- Tucker NR, Chaffin M, Bedi KC, Jr., Papangeli I, Akkad AD, Arduini A, Hayat S, Eraslan G, Muus
- 473 C, Bhattacharyya RP, et al. Myocyte-Specific Upregulation of ACE2 in Cardiovascular Disease:
- 474 Implications for SARS-CoV-2-Mediated Myocarditis. *Circulation*. 2020;142:708-710. doi:
- 475 10.1161/CIRCULATIONAHA.120.047911
- 476 35. Chung MK, Zidar DA, Bristow MR, Cameron SJ, Chan T, Harding CV, 3rd, Kwon DH, Singh T,
- 477 Tilton JC, Tsai EJ, et al. COVID-19 and Cardiovascular Disease: From Bench to Bedside. Circ Res.
- 478 2021;128:1214-1236. doi: 10.1161/CIRCRESAHA.121.317997
- 479 36. Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, Moller R, Jordan TX, Oishi K,
- 480 Panis M, Sachs D, et al. Imbalanced Host Response to SARS-CoV-2 Drives Development of
- 481 COVID-19. *Cell*. 2020;181:1036-1045 e1039. doi: 10.1016/j.cell.2020.04.026
- 482 37. Powell-Wiley TM, Poirier P, Burke LE, Despres JP, Gordon-Larsen P, Lavie CJ, Lear SA, Ndumele
- 483 CE, Neeland IJ, Sanders P, et al. Obesity and Cardiovascular Disease: A Scientific Statement
- 484 From the American Heart Association. Circulation. 2021;143:e984-e1010. doi:
- 485 10.1161/CIR.0000000000000973
- 486 38. Duncan MS, Greevy RA, Tindle HA, Vasan RS, Lipworth L, Aldrich MC, Lloyd-Jones DM,
- 487 Freiberg MS. Inclusion of Smoking Data in Cardiovascular Disease Risk Estimation. JAMA
- 488 *Cardiol.* 2022;7:195-203. doi: 10.1001/jamacardio.2021.4990
- 489 39. Duncan MS, Freiberg MS, Greevy RA, Jr., Kundu S, Vasan RS, Tindle HA. Association of
- Smoking Cessation With Subsequent Risk of Cardiovascular Disease. *JAMA*. 2019;322:642-650.
- 491 doi: 10.1001/jama.2019.10298
- 492 40. Leigh A, McEvoy JW, Garg P, Carr JJ, Sandfort V, Oelsner EC, Budoff M, Herrington D, Yeboah J.
- 493 Coronary Artery Calcium Scores and Atherosclerotic Cardiovascular Disease Risk Stratification
- 494 in Smokers. *JACC Cardiovasc Imaging*. 2019;12:852-861. doi: 10.1016/j.jcmg.2017.12.017
- 495 41. Joseph JJ, Deedwania P, Acharya T, Aguilar D, Bhatt DL, Chyun DA, Di Palo KE, Golden SH,
- Sperling LS, American Heart Association Diabetes Committee of the Council on L, et al.
- 497 Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes:
- 498 A Scientific Statement From the American Heart Association. *Circulation*.
- 499 2022;145:e722-e759. doi: 10.1161/CIR.000000000001040
- 500 42. Doi T, Langsted A, Nordestgaard BG. Elevated Remnant Cholesterol Reclassifies Risk of
- Ischemic Heart Disease and Myocardial Infarction. *J Am Coll Cardiol*. 2022;79:2383-2397. doi:
- 502 10.1016/j.jacc.2022.03.384
- 503 43. Trinder M, Francis GA, Brunham LR. Association of Monogenic vs Polygenic

504 Hypercholesterolemia With Risk of Atherosclerotic Cardiovascular Disease. JAMA Cardiol. 505 2020;5:390-399. doi: 10.1001/jamacardio.2019.5954 Patone M, Mei XW, Handunnetthi L, Dixon S, Zaccardi F, Shankar-Hari M, Watkinson P, Khunti 506 44. K, Harnden A, Coupland CAC, et al. Risks of myocarditis, pericarditis, and cardiac arrhythmias 507 associated with COVID-19 vaccination or SARS-CoV-2 infection. Nat Med. 2022;28:410-422. 508 509 doi: 10.1038/s41591-021-01630-0 Patone M, Mei XW, Handunnetthi L, Dixon S, Zaccardi F, Shankar-Hari M, Watkinson P, Khunti 510 45. 511 K, Harnden A, Coupland CAC, et al. Risk of Myocarditis After Sequential Doses of COVID-19 512 Vaccine and SARS-CoV-2 Infection by Age and Sex. Circulation. 2022;146:743-754. doi: 513 10.1161/CIRCULATIONAHA.122.059970 514 46. Klein NP, Lewis N, Goddard K, Fireman B, Zerbo O, Hanson KE, Donahue JG, Kharbanda EO, Naleway A, Nelson JC, et al. Surveillance for Adverse Events After COVID-19 mRNA 515 516 Vaccination. JAMA. 2021;326:1390-1399. doi: 10.1001/jama.2021.15072 517 47. Najjar-Debbiny R, Gronich N, Weber G, Khoury J, Amar M, Stein N, Goldstein LH, Saliba W. 518 Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients. Clin Infect Dis. 2023;76:e342-e349. doi: 10.1093/cid/ciac443 519 520 48. Sadoff J, Gray G, Vandebosch A, Cardenas V, Shukarev G, Grinsztejn B, Goepfert PA, Truyers C, 521 Fennema H, Spiessens B, et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine 522 against Covid-19. N Engl J Med. 2021;384:2187-2201. doi: 10.1056/NEJMoa2101544 Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, Brooks N, Smaja M, Mircus G, 523 49. Pan K, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 524 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide 525 526 vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021;397:1819-1829. doi: 10.1016/S0140-6736(21)00947-8 527 528 Figure legends 529 530 Figure 1. Flow diagram outlining the search strategy and study identification for 531 532 meta-analysis. 533 Figure 2. A meta-analysis of the combined multivariate relative risk of 19 534 535 outcomes. 536

Figure 3. A meta-analysis of the combined univariable the combined OR of 4

538 outcomes.

							Total length of follow up	NO	COVID Sample	-19	COVID Sa	9-19 Gr imple	coup	B	MI(kg/	<b>m²</b> )			\$	Smokin	g, %					1	Diabete	, %					High	choleste	rol, %					Vac	cinatio	ı, %		
Study	Country	Race	Study design	Total number of samples	Male %	Age at baseline	(months)							NO COVII	<b>D-</b>	OVID- 19	-	No CO	OVID-19		C	OVID-	-19	N	lo COV	VID-19		Co	OVID-1	9	N	lo COV	/ID-19		CO	VID-19		No.	o COVI	ID-19		COV	VID-19	
								Tot al	Male	Fem ale	Tot ]	Mal I	Fem ale	Me an	SD M	Ie S n D		es %	Sam ple	% 1	Yes Sa mpl	S % m	No Sa apl %	Yo Sam ple		No Sam ple		Yes Sam ple	Sa o pl	No m e		es %	No Sam ple	S % m	Yes a pl %	Sa mpl e	%	Yes Sam ple	5 %	No Sam ple	S % m	Yes a pl %	Sam ple	%
Benjamin Bowe 2022 <sup>19</sup>	America	Mixe d	retrospecti ve cohort study	928,123	89.85	63.20 (16.53)	12	443, 588	386,8 97	56,6 91	484, <i>4</i>	423, 100	61,4	29.9	5.3 31 3 (	1.0 6.0 ) 6	0 2,87 3,81 8	53. 84	2,46 0,91 1	46.	264, 5 344	54. 22 56 19	20, 45. 91 44	1,33 1,01 5	24. 95	4,00 3,71 4	75. 1 05	156, 3 173 2	2. 32 23 36	8, 67. 2 77	NA	N A	NA	N A	N A A	NA	N A	2,07 2,00 8	38. 84	3,26 2,71 9	61. 17 16 18	3, 35. 37 74	311, 347	64. 26
Benjamin Bowe 2023 <sup>4</sup>	America	Mixe d	retrospecti ve cohort study	6,124,045	90.00	62.84(16.27)	24	5,98 5,22 7	5,387 ,901	597, 326	138, 818	123, 687	15,1 31	30.2	5.7 30	5.7 ).3 5	3,40 9,68 5	56. 97	2,57 5,54 2	43. 03	79,1 5 40	57. 59 01 7	9,6 42. 78 99	1,71 6,56 3	28. 68	4,26 8,66 4	71. 4	40,4 2 38 1	9. 98. 3 80	,3 70. 0 87	NA	N A	NA	N A	A A	NA	N A	NA	N A	NA	N A	A N A	NA	N A
Eric Yuk Fai Wan 2023 <sup>3</sup>	China	NA	prospectiv e cohort study	149,749	48.08	65.85 (8.26)	18	142, 610	68,52 4	74,0 86	7,13	3,47 6	3,66	27.3	4.8 27	7.4 4.5	5 955	13. 38	6,18 4	86. 62	18,6	13. 12 06 98	23, 86. 88 94	NA	N A	NA	N A	NA .	N N A	A A	NA	N A	NA	N A	A N A	NA	N A	NA	N A	NA	N A	A N A	NA	N A
Gregory Y.H. Lip 2021 <sup>20</sup>	Britain	NA	prospectiv e cohort study	280,592	41.2	72.5 (9.9)	32	NA	NA	NA	NA	NA	NA	NA	N A	A A	NA	N A	NA	N A	NA	N A	IA NA	NA	N A	NA	N A	NA	N A	A A	NA	N A	NA	N A	A A	NA	N A	NA	N A	NA	N A	A N A	NA	N A
Hannah R Whittaker 2021 <sup>2</sup>	Britain	NA	retrospecti ve cohort study	494,513	44.32	44.38(16.79)			15,42																																			
Harrison G. Zhang 2022 <sup>30</sup> medRxiv	America preprint doi: I	NA	ve cohort  study org/10.1101/20; ied by peer re retrospecti	2,745,130 23.12.30.2330 view) is the a	00656; this uthor/funde	version posted E r, who has grant	14 December 31, 20 ted medRxiv a lid	23. The cense to	copyright h	nolder for e preprint	r this t in																																	
2022 <sup>21</sup>	America	Mixe d	It is made ava ve cohort study	illable under a 387,330	CC-BY-NC 45.26	C-ND 4:0 Interna (22.70)	tional license .	075	125,6 84	391	255	140, 147	190, 108	NA	N A	A A	NA	N A	NA	N A	NA	N A	IA NA	54,3 71	16. 46	275, 884	83. 6 54	82 6	3. 196 50 39	6, 76.	NA	N A	NA	N A	A A	NA	N A	NA	A I	NA	N A	A A	NA	N A
Ioannis Katsoularis 2021 <sup>28</sup>	Sweden	NA	retrospecti ve cohort study	435,223	NA	NA	7	348, 481	NA	NA	86,7 42	37 235	49 507	NA	N A	A A	NA	N A	NA	N A	NA	N A	IA NA	NA	N A	NA	N A	NA	N A	A N A	NA	N A	NA	N A	A N A	NA	N A	NA	N A	NA	N A	A N A	NA	N A
Ivan Chun Hang Lam 2023 <sup>22</sup>	China	NA	retrospecti ve cohort study	8,516,716	44.15	55.49(17.61)	28	4,26 0,01 5	1,877 ,970	2,38 2,04 5	4,25 6,70 1	1,88 1,76 1	2,37 4,94 0	NA	N A	A A	NA	N A	NA	N A	NA	N A	IA NA	488, 876	11. 48	3,77 1,13 9	88. <i>5</i>	539, 1 760 6	2. 3,7 6,9 68 1	71 87. 32	NA	N A	NA	N A	A N A	NA	N A	942, 186	22. 12	3,31 7,82 9	77. 94 88 67	1, 22. 8 12	3,31 5,02 3	77. 88
Ken Cohen 2021 <sup>29</sup>	America	Mixe d	retrospecti ve cohort study	5,652,190	42.30	73.85 (4.50)	24	5,51 8,82 4	2,332 ,984	3,18 5,84 0	133, 366	58,1 10	75,2 56	NA	N A	A A	304, 507	5.5	5,21 4,31 7	94. 48	5,87 <sup>4</sup>	4.4 12 1 48	27, 95. 88 59	54,5 58	40. 91	78,8 08	59. 09	1,69 1,13 1	0. 3,8 7,6 3	32 69. 36	NA	N A	NA	N A	A A	NA	N A	NA	N A	NA	N A	A N A	NA	N A
Kwan Hong 2022 <sup>17</sup>	South Korea	NA	retrospecti ve cohort study	2,30,327	47.46	NA	5	2,22 ,257	106,0 82	116, 175	8,07	3,23 6	4,83	NA	N A	A A	NA	N A	NA	N A	NA	N A	IA NA	30,0 05	13. 5	192, 252	86. 1 5	1,16 1 2	4. 6,9 4 8	90 85. 6	21,3 37	9.6	200, 920	90. 4	.5 10. 1	7,25 5	89. 9	NA	N A	NA	N A	A N A	NA	N A
Luis Ortega-Paz1 2022 <sup>23</sup>	Spain	NA	retrospecti ve cohort study	4,427	53.90	60.36(18.53)	12	849	354	495	3,57	2,03	1,54 6	26	5.0 28	3.4 5.3	3 283	33. 33	566	66. 67	958	26. 2,	62 73. 0 23	63	7.4 2	786	92. 58	721 1	0. 2,8	35 79. 85	NA	N A	NA	N A	A A	NA	N A	664	78. 21	185	21. 79	26. 55	2628	73. 45
Ortal Tuvali 2022 <sup>24</sup>	Israel	Mixe d	retrospecti ve cohort study	787,968	45.72	42.4 (17.70)	6	590, 976	270,2 10	320, 766	196, 992	90,0 70	106, 922	26.1	7.1 27	7.1 6.7	169, 7 467	28. 68	383, 002	64. 81	38,7	19. 13 67 0°	37, 69. 79 59	61,9 78	10. 49	528, 998	89. 2 51	25,5 1 83 9	2. 17 99 40	1, 87. 9 01	183, 704	31. 08	407, 272	68. 60 92 2	,6 30. 9 78	136, 363	69. 22	NA	N A	NA	N A	A A	NA	N A
Sithembile Mabila 2022 <sup>25</sup>	America	Mixe d	retrospecti ve cohort study	997,785	80.19	27.99 (7.96)	21	122, 424	98,99 0	23,4 34	875, 361	701, 090	174, 271	NA	N A	A A	NA	N A	NA	N A	NA	N A	IA NA	NA	N A	NA	N A	NA	N A	A A	NA	N A	NA	N A	A N A	NA	N A	NA	N A	NA	N A	A A	NA	N A
Weijie Wang 2022 <sup>16</sup>	China	Mixe d	retrospecti ve cohort study	1,381,156	43.16	43.15(16.15)	39	690, 604	298,2 23	392, 381	690, 552	297, 939	392, 613	NA	N A	A A	48,2 96	6.9 9	642, 596	93. 01	50,5 7 76	7.3 64 2 33	40, 92. 16 68	56,8 80	8.2	634, 102	91. <i>5</i>	57,6 8 23	.3 63: 4 26	3, 91. 69 66	59,6 39	8.6	631, 253	91. 60 37 0	,8 8.8 8 0	630, 084	91. 2	NA	N A	NA	N A	A N A	NA	N A
Yan Xie 2022 <sup>18</sup>	America	Mixe d	retrospecti ve cohort study	11,650,81 8	90.26	63.38 (16.26)	12	11,4 97,0 58	10,37 7,853	1,11 9,20 5	153, 760	137, 617	16,1 43	28.6	3.7 28 6 0	3.7 3.8 6 1	6,60 2,47 4	57. 43	4,89 4,70 0	42. 57	91,7 5 81	59. 61 69 7	1,9 40. '9 31	8,87 7,84 4	77. 22	2,61 9,21 4	22. 1 78 2	116, 7 256 6	5. 37, 51 04	,5 24. 4 39	8,54 1,31 1	74. 29	2,95 5,74 7	25. 11 71 92	1, 72. 22 79	41,8 38	27. 21	NA	N A	NA	N A	A N A	NA	N A
Zahra Raisi-Estabragh 2022 <sup>26</sup>	Britain	NA	prospectiv e cohort study	53,613	47.04	65(11.11)	13.2	35,7 42	16 ,8 13	18, 929	17,8 71	8,40 9	9,46 2	27.4	4.6 7	7.5 4.5 2	5 4,17 2	11. 67	31,5 70	88.	2,09	11. 15 73 7	5,7 88. 25 27	3,68	10. 30	32,0 59	89. 1 70	1,83 1 5 2	0. 16. 27 36	,0 89. 5 73	6,68 9	18. 71	29,0 53	81. 3,3 29 6	33 18. 5 67	14,5 35	81. 33	NA	N A	NA	N A	A N A	NA	N A
Ziyad Al-Aly 2021 <sup>27</sup>	America	Mixe d	retrospecti ve cohort study	5,064,270	90.42	66.59(16.37)	6.8	4,99 0,83 5	4,514 ,365	476, 470	73,4 35	54,5 55	8,88	NA	N A	A A	NA	N A	NA	N A	NA	N A	IA NA	NA	N A	NA	N A	NA	N A	A A	NA	N A	NA	N A	A A	NA	N A	NA	N A	NA	N A	A A	NA	N A

Table. 2 Quality assessment of the included studies in the meta-analysis.

Source	Selection	Comparability	Outcome	<b>Total Score</b>
Benjamin Bowe 2022 <sup>19</sup>	+++	++	+++	8
Benjamin Bowe 2023 <sup>4</sup>	++++	++	+++	9
Eric Yuk Fai Wan 2023 <sup>3</sup>	+++	++	++	7
Gregory Y.H. Lip 2021 <sup>20</sup>	++++	++	++	8
Hannah R Whittaker 2021 <sup>2</sup>	++++	++	++	8
Harrison G. Zhang 2022 <sup>30</sup>	+++	++	+	6
Husam M. Salah 2022 <sup>21</sup>	+++	++	++	7
Ioannis Katsoularis 2021 <sup>28</sup>	+++	++	+	6
Ivan Chun Hang Lam 2023 <sup>22</sup>	++++	++	++	8
Ken Cohen 2021 <sup>29</sup>	+++	++	+	6
Kwan Hong 2022 <sup>17</sup>	++++	++	+	7
Luis Ortega-Pazl 2022 <sup>23</sup>	++++	++	++	8
Ortal Tuvali 2022 <sup>24</sup>	++++	++	++	8
Sithembile Mabila 2022 <sup>25</sup>	+++	++	++	7
Weijie Wang 2022 <sup>16</sup>	+++	++	++	7
Yan Xie 2022 <sup>18</sup>	+++	++	++	7
Zahra Raisi-Estabragh 2022 <sup>26</sup>	++++	++	++	8
Ziyad Al-Aly 2021 <sup>27</sup>	++++	++	++	8

# PRISMA 2020 flow diagram for new systematic reviews which included searches of databases and registers only





